Rufinamide Tablets
Dosage form: tablet, film coated
Drug class:Dibenzazepine anticonvulsants
Medically reviewed by Drugs.com. Last updated on May 1, 2021.
On This Page
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Drug Interactions
- Use In Specific Populations
- Overdosage
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- How Supplied/Storage and Handling
- Patient Counseling Information
- Medication Guide
Indications and Usage for Rufinamide Tablets
Rufinamide Tablets are indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older and in adults.
Rufinamide Tablets Dosage and Administration
Dosage Information
Pediatric Patients (1 year to less than 17 years)The recommended starting daily dose of Rufinamide Tablets in pediatric patients with Lennox-Gastaut Syndrome is approximately 10 mg/kg administered in two equally divided doses. The dose should be increased by approximately 10 mg/kg increments every other day until a maximum daily dose of 45 mg/kg, not to exceed 3200 mg, administered in two equally divided doses, is reached. It is not known whether doses lower than the target doses are effective.
Adults (17 years and older)The recommended starting daily dose of Rufinamide Tablets in adults with Lennox-Gastaut Syndrome is 400 to 800 mg per day administered in two equally divided doses. The dose should be increased by 400 to 800 mg every other day until a maximum daily dose of 3200 mg, administered in two equally divided doses, is reached. It is not known whether doses lower than 3200 mg are effective.
Administration Information
Administer Rufinamide Tablets with food. Rufinamide film-coated tablets can be administered whole, as half tablets or crushed.
Dosing in Patients Undergoing Hemodialysis
Hemodialysis may reduce...
